Seeking Alpha

The return of $10B-plus drug deals may be here as pharmaceutical companies appear to be gearing...

The return of $10B-plus drug deals may be here as pharmaceutical companies appear to be gearing up to start buying again. Five of the largest U.S. drug makers have spent the last several years building up their cash positions in anticipation of expiring patents. Now, with nearly $70B in cash equivalents at their disposal, all eyes are on JPMorgan’s annual health-care conference in San Francisco, where the big drug makers will likely be on the hunt for assets to fill revenue holes left by expired patents.
Comments (2)
  • RSI Raistlin
    , contributor
    Comments (400) | Send Message
     
    vicl, clsn maybe?
    7 Jan 2013, 09:48 PM Reply Like
  • chopchop0
    , contributor
    Comments (3796) | Send Message
     
    This is why biotech has been an awesome sector to be in the last couple years. It's been hard to pick all the winners so I've stuck with the ETFs, IBB and XBI. despite being ETFs, they've done quite well in the last 1-2 years
    7 Jan 2013, 10:20 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs